Immunoprecise Antibodies Ltd (NASDAQ:IPA) — Stock Price
Immunoprecise Antibodies Ltd (NASDAQ:IPA) is currently trading at $2.07 USD, up 7.25% today. Over the past 52 weeks, shares have ranged between $1.93 and $3.20. This page tracks Immunoprecise Antibodies Ltd's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Immunoprecise Antibodies Ltd market capitalisation.
Immunoprecise Antibodies Ltd (IPA) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Immunoprecise Antibodies Ltd's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Immunoprecise Antibodies Ltd Income Statement — Revenue, Profit & Earnings by Year
Immunoprecise Antibodies Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $24.52 Million | $24.52 Million | $20.66 Million | $19.36 Million | $17.91 Million |
| Cost of Revenue | $10.97 Million | $12.46 Million | $9.10 Million | $8.38 Million | $6.37 Million |
| Gross Profit | $13.55 Million | $12.05 Million | $11.56 Million | $10.98 Million | $11.54 Million |
| Research & Development | $4.94 Million | $4.06 Million | $14.11 Million | $6.69 Million | $1.97 Million |
| SG&A | $14.73 Million | $15.59 Million | $15.38 Million | $16.97 Million | $12.65 Million |
| Total Operating Expenses | $25.74 Million | $25.82 Million | $37.17 Million | $27.66 Million | $15.71 Million |
| Operating Income | $-12.20 Million | $-13.76 Million | $-25.61 Million | $-15.78 Million | $-4.18 Million |
| EBITDA | $-28.86 Million | $-22.95 Million | $-21.04 Million | $-11.99 Million | $-1.42 Million |
| EBIT | $-33.97 Million | $-28.68 Million | $-27.72 Million | $-15.76 Million | $-5.13 Million |
| Interest Expense | $293.00K | $19.00K | $30.00K | $85.00K | $863.00K |
| Income Before Tax | $-34.27 Million | $-28.70 Million | $-27.75 Million | $-15.85 Million | $-6.00 Million |
| Income Tax Expense | $-4.03 Million | $-1.53 Million | $-1.19 Million | $861.00K | $1.34 Million |
| Net Income | $-30.23 Million | $-27.18 Million | $-26.56 Million | $-16.71 Million | $-7.34 Million |
Immunoprecise Antibodies Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Immunoprecise Antibodies Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $44.44 Million | $59.99 Million | $77.81 Million | $93.49 Million | $66.96 Million |
| Total Current Assets | $18.75 Million | $11.49 Million | $16.79 Million | $37.47 Million | $48.86 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | $4.81 Million | $4.07 Million | $4.42 Million | $3.41 Million | $4.12 Million |
| Inventory | $2.10 Million | $2.14 Million | $2.06 Million | $1.61 Million | $1.20 Million |
| Property, Plant & Equipment | — | — | $10.39 Million | $3.34 Million | $4.02 Million |
| Goodwill | $8.23 Million | $7.69 Million | $19.17 Million | $19.70 Million | $7.78 Million |
| Total Liabilities | $20.82 Million | $26.07 Million | $20.01 Million | $18.21 Million | $10.04 Million |
| Total Current Liabilities | $9.01 Million | $8.12 Million | $5.92 Million | $9.26 Million | $6.07 Million |
| Long-term Debt | — | — | — | — | $1.53 Million |
| Net Debt | $2.74 Million | $10.22 Million | $-1.01 Million | $-27.42 Million | $-38.30 Million |
| Total Stockholder Equity | $23.63 Million | $33.92 Million | $57.80 Million | $75.28 Million | $56.92 Million |
| Retained Earnings | $-128.79 Million | $-100.27 Million | $-73.09 Million | $-46.53 Million | $-29.82 Million |
Immunoprecise Antibodies Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Immunoprecise Antibodies Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-6.41 Million | $-4.25 Million | $-19.83 Million | $-9.92 Million | $-600.00K |
| Capital Expenditures | $799.00K | $1.40 Million | $1.50 Million | $1.26 Million | $1.43 Million |
| Free Cash Flow | $-7.21 Million | $-5.64 Million | $-21.33 Million | $-11.18 Million | $-2.03 Million |
| Investing Cash Flow | $-799.00K | $-1.56 Million | $-1.97 Million | $-5.21 Million | $-2.46 Million |
| Financing Cash Flow | $14.89 Million | $1.02 Million | $-621.00K | $2.88 Million | $43.38 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $445.00K | $1.53 Million | $1.94 Million | $3.08 Million | $2.75 Million |
| Depreciation | $5.12 Million | $5.74 Million | $6.68 Million | $3.77 Million | $3.71 Million |
| Change in Cash | $7.25 Million | $-4.82 Million | $-21.68 Million | $-11.79 Million | $39.15 Million |
Immunoprecise Antibodies Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Immunoprecise Antibodies Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jul 28, 2025 | -0.04 | -0.04 | -4.29% |
| Mar 12, 2025 | -0.46 | -0.06 | -724.82% |
| Dec 12, 2024 | -0.06 | -0.07 | +9.00% |
| Sep 16, 2024 | -0.11 | -0.08 | -37.50% |
| Jul 29, 2024 | -0.11 | -0.11 | +0.00% |
| Mar 14, 2024 | -0.11 | -0.10 | -10.00% |
| Dec 14, 2023 | -0.10 | -0.13 | +23.08% |
| Sep 14, 2023 | -0.14 | -0.20 | +30.00% |